ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0325

The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis
Abstract Number: 0326

Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)
Abstract Number: 0327

Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 0328

IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
Abstract Number: 0329

Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
Abstract Number: 0330

Baseline Interstitial Lung Disease (ILD) Characteristics and Outcomes in Patients with Anti-synthetase Syndrome Related ILD (ASSD-ILD): Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Abstract Number: 0331

Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Abstract Number: 0332

Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
Abstract Number: 0333

Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
Abstract Number: 0334

Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity
Abstract Number: 0335

Analysis of the Prevalence of Diabetes Mellitus in Patients with Adult-onset Dermatomyositis
Abstract Number: 0336

Mortality: Comparison, Causes and Determinants in Subgroups of Idiopathic Inflammatory Myopathies
Abstract Number: 0337

Characterization of Statin Induced Myopathy in the Hospital Setting
Abstract Number: 0338

Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
Abstract Number: 0339

Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].